Heron Therapeutics EBITDA 2010-2025 | HRTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Heron Therapeutics ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Heron Therapeutics ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$76.6B
Zoetis (ZTS)	$69B
Takeda Pharmaceutical (TAK)	$46.7B
Daiichi Sankyo, - (DSNKY)	$41.7B
BeOne Medicines - (ONC)	$27.4B
Sandoz Group AG (SDZNY)	$24.6B
Summit Therapeutics (SMMT)	$18.6B
Merck (MKKGY)	$17.2B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.3B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.3B
Stevanato Group S.p.A (STVN)	$7.6B
Corcept Therapeutics (CORT)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7B
Grifols, S.A (GRFS)	$6.7B
Ionis Pharmaceuticals (IONS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.1B
Crinetics Pharmaceuticals (CRNX)	$3B
Hypermarcas (HYPMY)	$3B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B